Safety Alerts & Recalls
What does this mean?
At this time, there have been no reports of safety issues with this recalled bupropion product. However, since the recalled tablets possibly contain impure inactive ingredients, it is best to avoid using the recalled medication. If you take bupropion, check your prescription bottle to see if your tablets are Twice a Day Bupropion Hydrochloride Extended-Release Tablets, 150 mg and were made by Actavis or Catalent. The manufacturer is often listed on the prescription label. You can also look on the label for the product code NDC 67767-133-60. If you think your tablets are involved in the recall or if you do not know, please return your bottle to your pharmacist to examine and possibly exchange.
If you have any questions or concerns about this recall, please follow up with your doctor or pharmacist. If you think you may be experiencing side effects from your Bupropion, please contact your doctor as soon as possible.
Recall of a Single Lot of Actavis / Catalent Bupropion Extended-Release Tablets 150 mg
Actavis South Atlantic LLC and Catalent Pharma Solutions have recalled a single lot number of Twice a Day Bupropion Hydrochloride Extended-Release Tablets, 150 mg, labeled with product code NDC 67767-133-60. The lot number 0805699A is being recalled because the tablets in this lot failed impurity tests and contain additional inactive ingredients.
Bupropion is used in the treatment of depression and is also used to help people stop smoking. Bupropion is sold under many different brand names (including Aplenzin, Wellbutrin and Zyban) and is available in different strengths. No other brands or strengths of bupropion are involved in this recall.
For more information, please visit: more information here